Development of a Mouse-Adapted Live Attenuated Influenza Virus That Permits In Vivo Analysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pa...

Full description

Saved in:
Bibliographic Details
Published in:J Virol
Main Authors: Cox, Andrew, Baker, Steven F., Nogales, Aitor, Martínez-Sobrido, Luis, Dewhurst, Stephen
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2014
Subjects:
Vaccines and Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337518/
https://ncbi.nlm.nih.gov/pubmed/25552727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02636-14
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items